22 active trials 10 recruiting 7 Phase 3 10 disease areas 4 changes in 30 days
3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
Primary and study completion pushed from Mar 2028 to Dec 2028
Stichting Hemato-Oncologie voor Volwassenen NederlandPhase 2 NCT06014489 Registry history of NCT06014489 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 82 → 97 locations
Stichting Hemato-Oncologie voor Volwassenen NederlandPhase 3 NCT07223814 Registry history of NCT07223814 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 24 → 29 locations
Stichting Hemato-Oncologie voor Volwassenen NederlandPhase 1/2 NCT05791409 Registry history of NCT05791409 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-06 | NCT07860775 Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With… | Phase 2 | Not Yet Recruiting |
| Phase 1/2 | 3 | |
| Phase 2 | 12 | |
| Phase 3 | 7 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by… | Acute Myeloid Leukemia | Recruiting | 2026-10-08 |
| NCT06220032 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With… | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting | 2026-09-23 |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… | Acute Myeloid Leukemia, Adult | Recruiting | 2026-09-02 |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly… | Acute Myeloid Leukemia | Recruiting | 2025-08-19 |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With… | Multiple Myeloma | Recruiting | 2024-08-19 |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and… | Acute Myeloid Leukemia | Active, Not Recruiting | 2026-09-22 |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and… | Acute Myeloid Leukemia | Active, Not Recruiting | 2024-12-17 |
| Phase 2 | ||||
| NCT06014489 | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult… | AML, Adult | Recruiting | 2026-09-23 |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | CLL/SLL | Recruiting | 2026-09-21 |
| NCT07860775 | Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With… | CLL / SLL | Not Yet Recruiting | 2026-10-06 |
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High… | NHL | Active, Not Recruiting | 2026-09-23 |
| NCT05502250 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab… | Hodgkin Lymphoma | Active, Not Recruiting | 2026-03-06 |
| NCT06067048 | Zanubrutinib in Primary Cold Agglutinin Disease | Lymphoma | Active, Not Recruiting | 2026-03-06 |
| NCT03541083 | Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute… | ALL, Adult | Active, Not Recruiting | 2024-09-19 |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High… | AML/MDS | Active, Not Recruiting | 2024-09-19 |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2… | Non Hodgkin Lymphoma | Active, Not Recruiting | 2024-02-14 |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in… | Smouldering Myeloma | Active, Not Recruiting | 2023-11-01 |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | Myelofibrosis | Active, Not Recruiting | 2022-08-22 |
| NCT04639362 | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and… | CLL | Active, Not Recruiting | 2021-08-23 |
| Phase 1/2 | ||||
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients… | CLL/SLL | Recruiting | 2026-10-05 |
| NCT06605586 | Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition | Myelofibrosis | Recruiting | 2025-03-07 |
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to… | DLBCL | Recruiting | 2020-12-10 |
Acute Myeloid Leukemia (AML) (7) · Leukemia (5) · Chronic Lymphocytic Leukemia (CLL) (4) · DLBCL (3) · Myelodysplastic Syndromes (MDS) (3) · Non-Hodgkin Lymphoma (3) · Multiple Myeloma (2) · Myelofibrosis (2) · Acute Lymphoblastic Leukemia (ALL) (1) · Hodgkin Lymphoma (1)